Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies
Human serum IgG contains multiple glycoforms which exhibit a range of binding properties to effector molecules such as cellular Fc receptors. Emerging knowledge of how the Fc glycans contribute to the antibody structure and effector functions has opened new avenues for the exploitation of defined antibody glycoforms in the treatment of diseases. Here, we review the structure and activity of antibody glycoforms and highlight developments in antibody glycoengineering by both the manipulation of the cellular glycosylation machinery and by chemoenzymatic synthesis. We discuss wide ranging applications of antibody glycoengineering in the treatment of cancer, autoimmunity and inflammation. This article is part of a Special Issue entitled «Glycans in personalised medicine» Guest Editor: Professor Gordan Lauc.
Antibody, Effector function, Glycan, Glycosylation, Structure, Therapeutic antibodies
1655-1668
Le, Ngoc Phuong Lan
a5b48632-122d-4b3d-8420-69ebded556f1
Bowden, Thomas A.
4b17a588-ac01-4112-807a-8b99a6c20d0f
Struwe, Weston B.
16a348b1-3921-4a2d-b5fb-d341fccea65f
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
1 August 2016
Le, Ngoc Phuong Lan
a5b48632-122d-4b3d-8420-69ebded556f1
Bowden, Thomas A.
4b17a588-ac01-4112-807a-8b99a6c20d0f
Struwe, Weston B.
16a348b1-3921-4a2d-b5fb-d341fccea65f
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Le, Ngoc Phuong Lan, Bowden, Thomas A., Struwe, Weston B. and Crispin, Max
(2016)
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies.
Biochimica et Biophysica Acta (BBA) - General Subjects, 1860 (8), .
(doi:10.1016/j.bbagen.2016.04.016).
Abstract
Human serum IgG contains multiple glycoforms which exhibit a range of binding properties to effector molecules such as cellular Fc receptors. Emerging knowledge of how the Fc glycans contribute to the antibody structure and effector functions has opened new avenues for the exploitation of defined antibody glycoforms in the treatment of diseases. Here, we review the structure and activity of antibody glycoforms and highlight developments in antibody glycoengineering by both the manipulation of the cellular glycosylation machinery and by chemoenzymatic synthesis. We discuss wide ranging applications of antibody glycoengineering in the treatment of cancer, autoimmunity and inflammation. This article is part of a Special Issue entitled «Glycans in personalised medicine» Guest Editor: Professor Gordan Lauc.
Text
1-s2.0-S0304416516301210-main
- Version of Record
More information
Accepted/In Press date: 16 April 2016
e-pub ahead of print date: 20 April 2016
Published date: 1 August 2016
Keywords:
Antibody, Effector function, Glycan, Glycosylation, Structure, Therapeutic antibodies
Identifiers
Local EPrints ID: 414328
URI: http://eprints.soton.ac.uk/id/eprint/414328
ISSN: 0304-4165
PURE UUID: 6ab8cb48-5b92-4780-964d-c7135c870b9f
Catalogue record
Date deposited: 26 Sep 2017 16:30
Last modified: 16 Mar 2024 04:30
Export record
Altmetrics
Contributors
Author:
Ngoc Phuong Lan Le
Author:
Thomas A. Bowden
Author:
Weston B. Struwe
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
